Elicio Therapeutics, Inc. (ELTX) Revenue History
Annual and quarterly revenue from 2012 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ELTX Revenue Growth
ELTX Revenue Analysis (2012–2025)
As of May 9, 2026, Elicio Therapeutics, Inc. (ELTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, ELTX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $28.3 million in 2021.
When compared to Healthcare sector peers including NKTR (-36.2% YoY), ADCT (+4.4% YoY), and IMCR (+15.6% YoY). Compare ELTX vs NKTR →
ELTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ELTXCurrent | $0 | - | - | - | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 ADCT | $81M | +4.4% | - | -133.2% | |
 IMCR | $298M | +15.6% | +58.1% | -11.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
ELTX Historical Revenue Data (2012–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-37,714,000 | - |
| 2024 | $0 | - | $-1,178,000 | - | $-44,986,000 | - |
| 2023 | $0 | - | $-1,170,000 | - | $-35,745,000 | - |
| 2022 | $0 | -100.0% | $-1,057,000 | - | $-23,733,000 | - |
| 2021 | $28.3M | +883.1% | $27.1M | 95.6% | $-39,307,000 | -138.8% |
| 2020 | $2.9M | +93.7% | $1.1M | 36.9% | $-55,273,000 | -1919.2% |
| 2019 | $1.5M | -63.1% | $351K | 23.6% | $-38,591,000 | -2595.2% |
| 2018 | $4.0M | -38.8% | $3.6M | 90.6% | $-14,342,000 | -356.0% |
| 2013 | $6.6M | -9.8% | $3.4M | 51.8% | $-397,800 | -6.0% |
| 2012 | $7.3M | - | $3.6M | 49.7% | $-419,220 | -5.7% |
See ELTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELTX — Frequently Asked Questions
Quick answers to the most common questions about buying ELTX stock.
Is ELTX's revenue growth accelerating or slowing?
ELTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ELTX's long-term revenue growth rate?
Elicio Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ELTX's revenue distributed by segment?
ELTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2012-2025 are available for download. Segment mix reveals concentration and diversification trends.